PCRX - Pacira BioSciences, Inc.

25.36
0.480   1.893%

Share volume: 646,612
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$24.88
0.48
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
36%
Profitability 26%
Dept financing 14%
Liquidity 70%
Performance 43%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.85%
1 Month
9.31%
3 Months
23.71%
6 Months
16.65%
1 Year
-2.46%
2 Year
-2.08%
Key data
Stock price
$25.36
P/E Ratio 
158.29
DAY RANGE
$24.70 - $25.48
EPS 
$0.16
52 WEEK RANGE
$18.80 - $27.64
52 WEEK CHANGE
-$1.40
MARKET CAP 
1.113 B
YIELD 
N/A
SHARES OUTSTANDING 
40.490 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
1.64
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$480,230
AVERAGE 30 VOLUME 
$503,411
Company detail
CEO: David M. Stack
Region: US
Website: pacira.com
Employees: 720
IPO year: 2011
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectionable suspension. iovera system produces controlled doses of cold temperature only to targeted nerves.

Recent news